Processing

Please wait...

Settings

Settings

Goto Application

1. WO2001060413 - RECOMBINANT VECTOR EXPRESSING A BETA2-ADRENERGIC RECEPTOR AND USE IN TREATING AIRWAY AND VASCULAR DISEASES

Publication Number WO/2001/060413
Publication Date 23.08.2001
International Application No. PCT/US2001/004832
International Filing Date 15.02.2001
Chapter 2 Demand Filed 17.09.2001
IPC
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 11/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 11/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
08Bronchodilators
C12N 15/86 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
CPC
A61K 48/005
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
005characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
A61K 48/0058
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
005characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 11/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
08Bronchodilators
C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
C12N 2750/14143
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2750ssDNA Viruses
00011ssDNA Viruses
14011Parvoviridae
14111Dependovirus, e.g. adenoassociated viruses
14141Use of virus, viral particle or viral elements as a vector
14143viral genome or elements thereof as genetic vector
Applicants
  • BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS [US]/[US] (AllExceptUS)
  • CORNETT, Lawrence, E. [US]/[US] (UsOnly)
  • HILLER, F., Charles [US]/[US] (UsOnly)
  • JONES, Stacie [US]/[US] (UsOnly)
Inventors
  • CORNETT, Lawrence, E.
  • HILLER, F., Charles
  • JONES, Stacie
Agents
  • PEET, Richard, C.
Priority Data
60/182,50215.02.2000US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) RECOMBINANT VECTOR EXPRESSING A BETA2-ADRENERGIC RECEPTOR AND USE IN TREATING AIRWAY AND VASCULAR DISEASES
(FR) ADMINISTRATION DE RECEPTEUR ADRENERGIQUE $G(B)2 DE RECOMBINAISON ET UTILISATION DANS LE TRAITEMENT DES MALADIES RESPIRATOIRES ET VASCULAIRES
Abstract
(EN)
A method of treating a human having airway or vascular disease comprises administering to at least one cell type selected from airway epithelial cells, airway smooth muscle cells, blood vessel endothelial cells, and blood vessel smooth muscle cells, a first composition comprising a vector comprising a DNA sequence encoding a $g(b)2AR ($g(b)2-adrenergic receptor) or a mutant thereof, operably linked to a promoter that is functional in at least one of said cells said subject, and optionally a second composition comprising at least one $g(b)2-adrenergic agonist. Pharmaceutical compositions comprising the vector comprising a DNA sequence encoding a $g(b)2AR or a mutant thereof, operably linked to a promoter that is functional in at least one of the cells of the subject and kits containing these compositions as well as.. An in vitro method of expressing the $g(b)2AR gene in mammalian cells and a method of evaluating the effect of pharmacological compounds on the expression of the $g(b)2AR gene is disclosed.
(FR)
L'invention concerne un procédé de traitement des maladies respiratoires et vasculaires chez l'homme, qui consiste à administrer à au moins un type de cellule (épithélial ou musculaire lisse des voies respiratoires, endothélial ou musculaire lisse des vaisseaux sanguins) une première composition renfermant un vecteur qui comprend une séquence d'ADN codant un récepteur adrénergique $g(b)2 ou un mutant correspondant, lié opérationnel à un promoteur fonctionnel dans au moins une cellule du sujet, sachant que la séquence codante est exprimée dans au moins une des cellules; et qui consiste éventuellement à administrer une seconde composition comprenant au moins un agoniste vis-à-vis du récepteur considéré dans les cellules du sujet. On peut en outre administrer une composition pharmaceutique qui renferme une hormone ou un agent pharmaceutique induisant chez le promoteur l'expression dudit récepteur dans au moins une des cellules cibles. L'invention concerne également des compositions pharmaceutiques renfermant le vecteur qui comprend une séquence d'ADN codant un récepteur adrénergique $g(b)2 ou un mutant correspondant, lié opérationnel à un promoteur fonctionnel dans au moins une des cellules du sujet, et des kits contenant lesdites compositions. L'invention concerne enfin un procédé <i>in vitro</i> relatif à l'expression du gène de ce récepteur dans des cellules mammaliennes et un procédé relatif à l'évaluation de l'effet de composés pharmacologiques sur l'expression dudit gène.
Also published as
Latest bibliographic data on file with the International Bureau